reports
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listin...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4)....
Annexon Accelerating Next Generation Targeted Immunotherapy Platform f...
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expect...
Annexon Submits Tanruprubart Marketing Authorization Application to th...
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it has submitted a Marketing Auth...
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthca...
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST. A live webcast of the event can be accessed under the ‘Events & Presenta...
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Progr...
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts – Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica has global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing...
- Jonathan Moreland
LTC LTC PROPERTIES INC.
ASA ASA
UA UNDER ARMOUR
FGBI INC.
GRX FIRST GUARANTY BANCSHARES
ANNX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
WRB ANNEXON
LUCY W.R. BERKLEY CORPORATION
PROP INNOVATIVE EYEWEAR INC
SUNS PRAIRIE OPERATING CO.
GF SUNRISE REALTY TRUST
FG THE NEW GERMANY FUND
INC.
F AND G ANNUITIES AND LIFE
INC.
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing ...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)...
- Jonathan Moreland
ALLE ALLEGION PLC
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SHBI SHORE BANCSHARES INC.
RPD RAPID7 INC.
NWBI NORTHWEST BANCSHARES INC.
HOO HERBALIFE NUTRITION LTD.
CALX CALIX NETWORKS
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
AP AMPCO-PITTSBURGH
GBLI GLOBAL INDEMNITY PLC
MSBI MIDLAND STATES BANCORP
INSE INSPIRED ENTERTAINMENT
WMG WARNER MUSIC GROUP CORP.
PMTS CPI CARD GROUP
BHC BAUSCH HEALTH COMPANIES INC.
VRCA VERRICA PHARMACEUTICALS
ESTC ELASTIC N.V.
ENR EDGEWELL PERSONAL CARE COMPANY
SELF SELF STORAGE GROUP
TBTC INC.
VLA TABLE TRAC INC.
ONEW ARBOR METALS
ABCL ONEWATER MARINE
ALIT ABCELLERA BIOLOGICS
BMEA ALIGHT
PBBK INC. / DELAWARE
NRDY BIOMEA FUSION
OWL INC.
ENOV PB BANKSHARES
QDEL INC.
J NERDY INC.
MAIA BLUE OWL CAPITAL INC
SMRT ENOVIS CORPORATION
FISV QUIDEL CORP
PODC JACOBS SOLUTIONS INC.
GAM MAIA BIOTECHNOLOGY INC
NUTX SMARTRENT INC
BAER FISERV
TENX INC.
SGI COURTSIDE GROUP INC.
AFCG GENERAL DE ALQUILER DE MAQUINARIA
DSM NUTEX HEALTH INC
XELB WILDFIRE NEW PUBCO
ANNX INC.
KTTA TENAX THERAPEUTICS INC.
SOMNIGROUP INTERNATIONAL INC.
AFC GAMMA
INC.
DREYFUS STRATEGIC MUNICIPAL BOND FUND
INC.
XCEL BRANDS INC.
ANNEXIN PHARMACEUTICALS AB (PUBL)
PASITHEA THERAPEUTICS CORP
- Jonathan Moreland
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SLGN SILGAN HOLDINGS INC.
RPD RAPID7 INC.
OPK OPKO HEALTH INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
GBCI GLACIER BANCORP INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FOXF FOX FACTORY HOLDING CORP.
EIG EMPLOYERS HOLDINGS INC.
ARCC ARES CAPITAL CORPORATION
RLMD RELMADA THERAPEUTICS
TREX TREX COMPANY INC.
VVV VALVOLINE INC.
KREF KKR REAL ESTATE FINANCE TRUST
HLNE HAMILTON LANE INCORPORATED CLASS A
SONO SONOS
VRCA VERRICA PHARMACEUTICALS
AMCR AMCOR PLC
AVTR AVANTOR
TSLX INC.
VLA SIXTH STREET SPECIALTY LENDING
MRVI INC.
FRSH ARBOR METALS
SG MARAVAI LIFESCIENCES HOLDINGS
TBBK FRESHWORKS INC.
QDEL SWEETGREEN INC
BHVN THE BANCORP
WEST INC.
SMRT QUIDEL CORP
CRVO BIOHAVEN LTD
NCDL WESTROCK COFFEE COMPANY LLC
GAM SMARTRENT INC
STRZ CERVOMED INC
GMRE NUVEEN CHURCHILL DIRECT LENDING CORP
OESX GENERAL DE ALQUILER DE MAQUINARIA
STARZ ENTERTAINMENT CORP
GLOBAL MEDICAL REIT INC.
ORION ENERGY SYSTEMS INC
- Jonathan Moreland
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
GLP GLOBAL PARTNERS LP
DIN DINE BRANDS GLOBAL INC.
RIGN TRANSOCEAN LTD.
AP AMPCO-PITTSBURGH
KYN KAYNE ANDERSON MLP INVESTMENT CO.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
MLP MAUI LAND & PINEAPPLE CO. INC.
GSHD GOOSEHEAD INSURANCE
VRCA VERRICA PHARMACEUTICALS
AEYE AUDIOEYE INC
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
UTZ UTZ BRANDS INC (A)
ABCL ABCELLERA BIOLOGICS
PBBK PB BANKSHARES
NEXT INC.
BBWI NEXT CAPITAL
EVLV BATH & BODY WORKS INC
ENOV EVOLV TECHNOLOGIES HLDGS INC
QDEL ENOVIS CORPORATION
J QUIDEL CORP
EBC JACOBS SOLUTIONS INC.
WEST EASTERN BANKSHARES INC
SMRT WESTROCK COFFEE COMPANY LLC
GTE SMARTRENT INC
MNR GRAN TIERRA ENERGY INC.
GAM MACH NATURAL RESOURCES LP
SPRU GENERAL DE ALQUILER DE MAQUINARIA
GF SPRUCE POWER HOLDING CORP
THE NEW GERMANY FUND
INC.
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
POST POST HOLDINGS INC.
NWBI NORTHWEST BANCSHARES INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
GLP GLOBAL PARTNERS LP
CALX CALIX NETWORKS
GAM GENERAL AMERICAN INVESTORS CO. INC.
PBI PITNEY BOWES INC.
RIGN TRANSOCEAN LTD.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
PED PEDEVCO CORP
VRCA VERRICA PHARMACEUTICALS
ONEW ONEWATER MARINE
BBWI BATH & BODY WORKS INC
EVLV EVOLV TECHNOLOGIES HLDGS INC
QDEL QUIDEL CORP
J JACOBS SOLUTIONS INC.
EBC EASTERN BANKSHARES INC
SMRT SMARTRENT INC
GTE GRAN TIERRA ENERGY INC.
MNR MACH NATURAL RESOURCES LP
RMI RIVERNORTH OPPOR MUN INC FD INC
Verrica Pharmaceuticals Announces Private Placement Financing of $50 M...
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027Financing anchored by Caligan Partners LP and PBM Capital, along with new and existing investors; Caligan Partners entitled to designate a new member to Verrica’s Board of Directors WEST CHESTER, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company ...
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results – Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program for VP-315 in basal cell carcinoma; Company presented new data on VP-315 at the recent Society for Immunotherapy of Cancer conference – – Received positive feedback from European Medicines Agency that supports a Marketing Authorization Application filing for YCANTH...
Annexon Announces Closing of Public Offering and Full Exercise of Unde...
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the closing of its previously announced underwritten public offering of 29,423,075 shares of its common stock, which includes the full exercise of the unde...
Annexon Announces Pricing of $75 Million Public Offering of Common Sto...
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock at a price to the public of $2.60 per share and, in lieu of shares of common stock to certain investor...
Annexon Announces Proposed Public Offering of Common Stock and Pre-Fun...
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Annexon. In addit...
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progre...
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline ARCHER II Pivotal Data for Vonaprument in Dry AMD with GA on Track for Second Half of 20...
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 C...
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting – Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells – – Findings provide mechanistic immunologic support for clinical efficacy previously reported, including 97% calculated objective response rate and 51% complete histologic clearance rate – – Coupled with VP-315’s ...
Verrica Pharmaceuticals Receives Positive Feedback from the European M...
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union – EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additional Phase 3 studies are required – – Verrica is initiating activities to support this regulatory submission, which could be filed as early as Q4 2026 – WEST CHESTER, Pa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.